🔎 Trials Near Me

Home › Lung Cancer › Washington

Lung Cancer clinical trials in Washington

43 studies for Lung Cancer are looking for participants at sites in Washington.

Cities in Washington

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Washington, Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Providence Regional Cancer System-Aberdeen, Aberdeen
  • PeaceHealth Saint Joseph Medical Center, Bellingham
  • Providence Regional Cancer System-Centralia, Centralia
  • and 19 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Oct 1, 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Kadlec Clinic Hematology and Oncology, Kennewick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT04181060

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  • University of Washington - Fred Hutchinson Cancer Center, Seattle
  • Compass Oncology, Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • American Oncology Network Vista Oncology Division-West office, Olympia
  • American Oncology Network Vista Oncology Division-East office, Olympia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  • Swedish Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Edmonds
  • Research Site, Seattle
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550

Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial

  • Muckleshoot Tribal Clinic, Auburn
  • South Puget Intertribal Planning Agency (SPIPA), Shelton
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07176000

A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingHealthy volunteers welcome
Ages 50 to 77 · All sexes · Updated Sep 17, 2026 · NCT07490860

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Swedish Cancer Institute - Edmonds, Edmonds
  • Kadlec Clinic Hematology and Oncology, Kennewick
  • Swedish Medical Center, Seattle
  • and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Seattle
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • Fred Hutchinson Cancer Center, Seattle
  • Northwest Medical Specialties, Tacoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06343402

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Madigan Army Medical Center, Tacoma
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07322341

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Virginia Mason Medical Center, Seattle
  • Legacy Cancer Institute Medical Oncology and Day Treatment, Vancouver
  • Legacy Salmon Creek Hospital, Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05624996

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06518057

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Recruiting
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT04151940

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07444814

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05098210

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Fred Hutch Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06162221

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Seattle Cancer Care Alliance, Seattle
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jun 26, 2026 · NCT04614103

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05570825

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06051695

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • FHCC Overlake, Bellevue
  • FHCC at EvergreenHealth, Kirkland
  • Valley Medical Center, Renton
  • and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572

MYLUNG Consortium Part 3: Observational Study

  • Northwest Cancer Specialists, P.C., Vancouver
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT05885698

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  • Virginia Mason Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • Virginia Mason Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT07020221

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.